Homeopathic Drug Product Safety, Quality, and Transparency Act

Bill Number

H.R. 7050

Origin Chamber

House

Congress

119th Congress, Session 2

Policy Area

Health

Status

Introduced

Latest Action

2026-01-14: Referred to the House Committee on Energy and Commerce.

Last Updated

2026-05-21T08:07:23Z

AI-Generated Summary

Purpose of the Legislation

The Homeopathic Drug Product Safety, Quality, and Transparency Act (H.R. 7050) aims to ensure continued access to safe homeopathic drug products for consumers and health care providers by creating a specific regulatory framework under the Federal Food, Drug, and Cosmetic Act (FD&C Act). It emphasizes safety, quality, and clear labeling while avoiding overly restrictive rules that could limit availability. Congress expresses the view that homeopathic medicines are valued by millions of Americans and that a dedicated legal pathway, rather than broad regulations, best protects access without blocking safe products.

Key Provisions

• Definitions: Updates the FD&C Act to define a "homeopathic drug product" as one containing only homeopathic ingredients (substances listed in the Homeopathic Pharmacopoeia of the United States, state formularies, or recognized standards) with no other active ingredients. It excludes these products from being classified as "new drugs," meaning they do not require pre-approval like conventional drugs.

• Regulatory Framework (New Section 503E of the FD&C Act):
• Limits most FD&C Act rules (e.g., premarket approval, new drug applications) from applying to homeopathic products, except for basic safety (adulteration), labeling (misbranding), and registration/listing requirements.
• Safety and Manufacturing: Products are adulterated (unsafe or impure) if they fail to meet standards from the Homeopathic Pharmacopoeia or accredited consensus standards. If no such standards exist, FDA good manufacturing practices (GMP) apply, but with options for homeopathic-specific rules developed via public input and advice from a new committee. Manufacturers can petition for exemptions or alternatives if they ensure safety; FDA must decide within 180 days or the petition is automatically approved.
• Testing: Exempts final products from certain identity/strength tests but requires checks for contaminants. For risky starting materials (e.g., toxic substances before dilution), intermediate steps must ensure safe levels, defined by recognized standards or below detectable amounts.
• Labeling and Misbranding: Prohibits non-homeopathic products from using terms like "homeopathic." Homeopathic products must use dilution notations (e.g., "3x" or "6c") and, for retail sale, include supported uses for minor self-limiting conditions (backed by pharmacopeias, medical references, journals, clinical data, or real-world evidence), plus a disclaimer: "These indications have not been evaluated by the Food and Drug Administration. This product is intended for traditional homeopathic uses." Labels must disclose sources or use a QR code if space is limited. Compliant labeling protects against false advertising claims under FTC rules or state laws, and no private lawsuits can rely on lack of clinical trials.
• Registration: FDA must separately designate and list homeopathic facilities and products.
• No Premarket Review: FDA cannot require approval before marketing.
• Advisory Committee: Establishes a permanent Homeopathic Drug Product Advisory Committee (10 members from consumer groups, manufacturers, pharmacopeia, practitioners like MDs, NDs, pharmacists, and vets, plus FDA Commissioner) to advise on regulations, review petitions, and investigate adverse events. Meets at least quarterly; no compensation for members.
• Enforcement: Inspectors must be trained on homeopathic standards. U.S. government bears burden of proof in violations; courts review de novo (fresh evaluation). Does not override state laws on homeopathy practice.

• Conforming Amendments: Updates related FD&C Act sections to include homeopathic products in supply chain rules, adverse event reporting for over-the-counter drugs, and excludes them from biological product regulations.

• Withdrawal of Guidance: Revokes FDA's 2022 guidance on homeopathic products, replacing it with these statutory rules.

• Severability: If any part is ruled invalid, the rest remains in effect.

Significant Changes to Existing Law

• Distinct Pathway: Introduces a tailored regulatory track for homeopathic products, exempting them from the FD&C Act's "new drug" requirements (e.g., no need for safety/efficacy proof via clinical trials before sale), which previously treated them like conventional drugs under enforcement discretion or guidance.
• Replaces Guidance with Statute: Nullifies the 2022 FDA guidance, shifting from agency policy to enforceable law with specific exemptions, standards, and committee input.
• Labeling and Claims Protections: Adds disclaimer requirements and shields compliant products from broader false advertising laws or lawsuits, reducing liability compared to current vague rules.
• Burden Shift and Flexibility: Places proof burden on the government (not manufacturers) and allows automatic petition approvals if FDA delays, contrasting with stricter conventional drug oversight.
• Committee Creation: Mandates a new advisory body, bypassing general FDA advisory processes for homeopathy-specific advice.

Potential Impacts

• Government Agencies: FDA gains a structured but lighter oversight role (e.g., no premarket reviews, but must create the committee, process petitions, train inspectors, and set safe levels for substances), potentially reducing workload on approvals while increasing post-market monitoring via adverse event reviews. Other agencies like FTC face limits on challenging compliant homeopathic claims.
• Citizens and Consumers: Improves access to homeopathic remedies for self-limiting conditions with clearer, safer labeling and disclaimers, potentially boosting informed use without FDA "evaluation" claims. May reduce confusion over product safety but does not guarantee efficacy.
• Health Care Providers: Enables easier integration of homeopathy in practices (e.g., by MDs, naturopaths, vets) without federal pre-approval hurdles, while preserving state licensing.
• Manufacturers and Businesses: Simplifies market entry and listing for small/large producers, with petition options for custom rules, but enforces stricter adulteration checks and disclosures. Could lower costs versus full drug approval but increase compliance for labeling/testing.
• International Relations: Minimal direct impact, though recognition of foreign pharmacopeias or standards may indirectly support global homeopathy trade.

Main Stakeholders Affected

• Consumers: Millions using homeopathic products for minor ailments, gaining safer access and transparent info.
• Manufacturers: Domestic homeopathic producers (small and large firms producing 50+ products), who benefit from exemptions but must meet pharmacopeia standards.
• Health Care Providers: Licensed practitioners (e.g., MDs/DOs with homeopathy certifications, naturopaths, pharmacists, veterinarians) involved in prescribing or preparing products.
• Consumer and Professional Groups: Organizations like homeopathic consumer associations and the Homeopathic Pharmacopoeia Convention, influencing the advisory committee.
• Government: Primarily FDA (regulation, committee management) and FTC (advertising oversight).

Notable Legal, Constitutional, or Political Implications

• Legal: Establishes de novo court review and government burden of proof, potentially making enforcement harder for FDA but providing predictability for industry. Protects against private lawsuits over unsubstantiated claims, limiting class actions. Non-preemption clause respects state authority on homeopathy practice, avoiding federalism conflicts.
• Constitutional: Severability ensures the law's core survives partial invalidation (e.g., if committee structure is challenged). No direct free speech or due process issues, but advisory committee setup must comply with federal rules on balance and expertise.
• Political: Promotes alternative medicine by codifying access over stringent science-based regulation, appealing to advocates of consumer choice and traditional remedies. Could spark debate on public health risks versus innovation, influencing future FDA policies on supplements or integrative care. Introduced by bipartisan sponsors, it signals congressional intent to tailor regulations for niche products without full conventional oversight.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Rep. Sessions, Pete [R-TX-17]

Cosponsors (4)

Rep. Kennedy, Mike [R-UT-3], Rep. Jackson, Jonathan L. [D-IL-1], Rep. Owens, Burgess [R-UT-4], Rep. Mills, Cory [R-FL-7]

Recent Actions

• 2026-01-14: Referred to the House Committee on Energy and Commerce.
• 2026-01-14: Introduced in House
• 2026-01-14: Introduced in House

Bill Versions

• Homeopathic Drug Product Safety, Quality, and Transparency Act — issued 2026-01-14 — PDF (22 pages)